Sperandeo M, Varriale A, Sperandeo G, Carughi S, Lucentini L
IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia.
Recenti Prog Med. 1993 Mar;84(3):225-30.
In the last 10 years, interest about the employment of bile acids, especially of ursodeoxycholic acid (UDCA), in the treatment of chronic liver diseases has increased. The mechanism has not been completely explained yet, but this agent has been thought to act mainly by making bile less toxic for the liver cells, reducing the fraction of hydrophobic detergent bile acids. UDCA is effective in decreasing serum concentrations of liver enzymes in chronic liver diseases, especially in those associated with cholestasis. This effect discloses new perspectives about the employment of this agent, even in association with other drugs, i.e. interferon; however, further investigations will be necessary in order to standardize the use of UDCA in the treatment of chronic liver diseases.
在过去10年中，人们对使用胆汁酸尤其是熊去氧胆酸（UDCA）治疗慢性肝病的兴趣有所增加。其作用机制尚未完全阐明，但人们认为该药物主要通过降低胆汁对肝细胞的毒性、减少疏水性去污剂胆汁酸的比例来发挥作用。UDCA可有效降低慢性肝病患者血清肝酶浓度，尤其是与胆汁淤积相关的慢性肝病。这一作用为该药物的应用，甚至与其他药物（如干扰素）联合应用，开辟了新的前景；然而，为了规范UDCA在慢性肝病治疗中的应用，还需要进一步研究。
